Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s camizestrant PDUFA date; and more
Plus news about Kailera, Alfasigma, Junshi and Kura.
⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
AstraZeneca breast cancer pill faces review delay from regulators
Pharmalittle: We're reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s…
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA,…
